Want to see JP:4886 full AI Analyst Report?
4886 Stock Chart & Stats
¥2038.00
-¥23.00(-1.13%)
At close: 4:00 PM EST
¥2038.00
-¥23.00(-1.13%)
Day’s Range― - ―
52-Week Range¥1,920.00 - ¥3,045.00
Previous CloseN/A
Volume48.10K
Average Volume (3M)49.10K
Market Cap
¥59.72B
Enterprise Value¥73.89K
Total Cash (Recent Filing)¥11.02B
Total Debt (Recent Filing)¥11.43B
Price to Earnings (P/E)11.7
Beta0.60
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.67%
Share Statistics
EPS (TTM)191.08
Shares Outstanding28,763,199
10 Day Avg. Volume37,820
30 Day Avg. Volume49,100
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)0.96
Price to Sales (P/S)0.94
P/FCF Ratio17.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)197.8
Revenue Forecast (FY)¥71.06B
Bulls Say, Bears Say
Bulls Say
Strengthened Balance SheetA materially lower debt burden and larger equity base improve financial flexibility and reduce refinancing risk over multiple years. This durable balance-sheet repair supports sustained R&D investment, protects against reimbursement shocks, and enhances the company’s ability to fund pipeline progression and M&A if needed.
Consistent Revenue ExpansionMulti-year, steady top-line growth indicates enduring demand for core branded products and effective commercialization in Japan. Persistent revenue expansion provides a reliable base to absorb pricing pressures and fund long-term initiatives like lifecycle management and selective pipeline investments.
Healthy Profitability And ScaleSustained gross-profit strength and recurring profitability reflect efficient manufacturing and a favorable product mix. Scale advantages and margin resilience support continued funding for R&D and commercialization while enabling defensive pricing tactics and reinvestment even if individual product cycles fluctuate.
Bears Say
Volatile Cash GenerationIrregular operating and free cash flow reduces predictability of internal funding for R&D, capex, and dividends. Over a 2–6 month to multi-year horizon, this volatility can force reliance on external financing or deferments, weakening strategic execution and making budgeting for pipeline advancement harder.
Earnings Volatility Year-to-yearCyclic or uneven net income limits the company’s ability to consistently reinvest and deliver predictable returns. For investors and management, this translates into greater operational risk when planning launches or M&A, and could pressure margins or force cost adjustments during weaker years.
Fluctuating Return On EquityVariable ROE signals inconsistent profit efficiency and capital allocation outcomes. Over the medium term this reflects uncertainty around how effectively incremental capital is converted to profits, which can weigh on long-term growth prospects and complicate investor assessment of management execution.
ASKA Pharmaceutical Holdings Co., Ltd. News
4886 FAQ
What was ASKA Pharmaceutical Holdings Co., Ltd.’s price range in the past 12 months?
ASKA Pharmaceutical Holdings Co., Ltd. lowest stock price was ¥1920.00 and its highest was ¥3045.00 in the past 12 months.
What is ASKA Pharmaceutical Holdings Co., Ltd.’s market cap?
ASKA Pharmaceutical Holdings Co., Ltd.’s market cap is ¥59.72B.
When is ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date?
ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date is Aug 04, 2026 which is in 13 days.
How were ASKA Pharmaceutical Holdings Co., Ltd.’s earnings last quarter?
ASKA Pharmaceutical Holdings Co., Ltd. released its earnings results on May 11, 2026. The company reported ¥53.53 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is ASKA Pharmaceutical Holdings Co., Ltd. overvalued?
According to Wall Street analysts ASKA Pharmaceutical Holdings Co., Ltd.’s price is currently Overvalued.
Does ASKA Pharmaceutical Holdings Co., Ltd. pay dividends?
ASKA Pharmaceutical Holdings Co., Ltd. pays a Semiannually dividend of ¥32 which represents an annual dividend yield of 2.67%. See more information on ASKA Pharmaceutical Holdings Co., Ltd. dividends here
What is ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate?
ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ASKA Pharmaceutical Holdings Co., Ltd. have?
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding.
What happened to ASKA Pharmaceutical Holdings Co., Ltd.’s price movement after its last earnings report?
ASKA Pharmaceutical Holdings Co., Ltd. reported an EPS of ¥53.53 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.057%.
Which hedge fund is a major shareholder of ASKA Pharmaceutical Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedicated to the research, development, production, and commercialization of medications, with a specific focus on endocrinology, obstetrics and gynecology, and urology. Within its animal health segment, ASKA manufactures, sells, imports, and exports a broad spectrum of veterinary products, such as medicines, medical equipment, animal feed and supplements, laboratory reagents, agricultural chemicals, industrial chemicals, hygiene products, and food items along with their raw materials. Beyond these activities, the company also performs clinical and biological testing and offers medical devices. Founded in 1920, ASKA Pharmaceutical Holdings Co.,Ltd. is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―